

---

## Product Data Sheet

---

Product Name: Vutiglabridin

Cat. No.: GC70139

### Chemical Properties

Cas. No. 1800188-47-9

Formula  $C_{22}H_{26}O_4$

M.Wt 354.44

Solubility DMSO : 100 mg/mL (282.14 mM; Need ultrasonic) Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure

### Background

Vutiglabridin (HSG4112), a racemic compound, is a potent anti-obesity agent<sup>[1]</sup>. Vutiglabridin, an optimized structural analog of Glabridin, markedly supersedes Glabridin in weight reduction efficacy and chemical stability<sup>[1]</sup>.

Vutiglabridin (HSG4112) fully reverses adiposity in HFD-induced obese mice in a dose-dependent manner. Vutiglabridin (orally administered with 10, 30, or 100 mg/kg dose for 6 weeks) dose-dependently reduces body weight and normalizes obesity-related parameters in high-fat diet (HFD)-induced obese mice<sup>[2]</sup>.

Animal Model: HFD-induced obese male C57BL/6J mice<sup>[2]</sup>

Dosage: 10, 30, and 100 mg/kg

Administration: Orally administered for 6 weeks

Result: Led to significant dose-dependent body weight reduction by 4.0 g (8.3%), 10 g (21%), and 19 g (40%), respectively, compared to the 48.1 g body weight of HFD-induced obese mice administered with only the vehicle at 10, 30, and 100 mg/kg.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

## Product Data Sheet

---

- [1]. In Yong Bae, et al. Species Differences in Stereoselective Pharmacokinetics of HSG4112, A New Anti-Obesity Agent. *Pharmaceutics*. 2020 Feb 3;12(2):127.
- [2]. Leo Sungwong Choi, et al. Discovery and preclinical efficacy of HSG4112, a synthetic structural analog of glabridin, for the treatment of obesity. *Int J Obes (Lond)*. 2021 Jan;45(1):130-142.

**Caution: Product has not been fully validated for medical applications. For research use only.**

**Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com**

**Address: 10292 Central Ave. #205, Montclair, CA, USA**